Exercise of Options and Total Voting Rights
28 January 2021
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 16,666 new ordinary shares of 4 pence each in the capital of the Company (“Ordinary Shares”) following the exercise of share options under the Company’s Third Unapproved Share Option scheme by certain option holders.
Application has been made to the London Stock Exchange for the 16,666 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2021.
After Admission, the total number of Ordinary Shares in issue will be 180,017,154 and the total number of voting rights will therefore be 180,017,154. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
|Omega Diagnostics Group PLC||Tel: 01259 763 030|
|Colin King, Chief Executive||www.omegadiagnostics.com|
|Kieron Harbinson, Group Finance Director|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash / Teddy Whiley (Corporate Finance)|
|Alice Lane (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Cawthorne||Mob: 07584 391 303|